Literature DB >> 12458157

Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy.

Lucila Garcia-Contreras1, Anthony J Hickey.   

Abstract

This review addresses different aerosol therapies used to treat the underlying cause and symptoms of cystic fibrosis (CF) during the past two decades. A summary of the current methods of aerosol delivery and suggestions that may improve the efficacy of the current treatments are provided. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12458157     DOI： 10.1016/s0169-409x(02)00159-x

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN： 0169-409X            Impact factor:   15.470


  10 in total

1.  Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus.

Authors:  Samuel K Lai; D Elizabeth O'Hanlon; Suzanne Harrold; Stan T Man; Ying-Ying Wang; Richard Cone; Justin Hanes
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-23       Impact factor: 11.205

2.  Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier.

Authors:  Ying-Ying Wang; Samuel K Lai; Jung Soo Suk; Amanda Pace; Richard Cone; Justin Hanes
Journal:  Angew Chem Int Ed Engl       Date:  2008       Impact factor: 15.336

3.  Evaluation of the Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis.

Authors:  John Denyer; Ivan Prince; Emma Dixon; Penny Agent; Jennifer Pryor; Margaret Hodson
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

4.  The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles.

Authors:  Jung Soo Suk; Samuel K Lai; Ying-Ying Wang; Laura M Ensign; Pamela L Zeitlin; Michael P Boyle; Justin Hanes
Journal:  Biomaterials       Date:  2009-01-26       Impact factor: 12.479

5.  Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier.

Authors:  Benjamin C Tang; Michelle Dawson; Samuel K Lai; Ying-Ying Wang; Jung Soo Suk; Ming Yang; Pamela Zeitlin; Michael P Boyle; Jie Fu; Justin Hanes
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-09       Impact factor: 11.205

6.  Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency.

Authors:  Chiara Parlati; Paolo Colombo; Francesca Buttini; Paul M Young; Handoko Adi; Alaina J Ammit; Daniela Traini
Journal:  Pharm Res       Date:  2009-01-31       Impact factor: 4.200

7.  Surfactant-free, biodegradable nanoparticles for aerosol therapy based on the branched polyesters, DEAPA-PVAL-g-PLGA.

Authors:  L A Dailey; E Kleemann; M Wittmar; T Gessler; T Schmehl; C Roberts; W Seeger; T Kissel
Journal:  Pharm Res       Date:  2003-12       Impact factor: 4.200

8.  Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.

Authors:  Yan Yang; Michael D Tsifansky; Chia-Jung Wu; Hae In Yang; Gudrun Schmidt; Yoon Yeo
Journal:  Pharm Res       Date:  2009-10-22       Impact factor: 4.200

9.  Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery.

Authors:  Jinghua Duan; Frederick G Vogt; Xiaojian Li; Don Hayes; Heidi M Mansour
Journal:  Int J Nanomedicine       Date:  2013-09-17

Review 10.  Nanotechnology approaches for inhalation treatment of fibrosis.

Authors:  Ronak Savla; Tamara Minko
Journal:  J Drug Target       Date:  2013-08-27       Impact factor: 5.121
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.